Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AIMTNASDAQ:APHANYSE:BKDNASDAQ:CORT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMTAimmune Therapeutics$34.49$34.46$10.09▼$37.00$2.26B1.761.71 million shsN/AAPHAAphria$15.38$15.48$2.78▼$32.29$4.87B2.6721.83 million shsN/ABKDBrookdale Senior Living$6.96+1.5%$6.25$3.33▼$7.05$1.32B1.321.84 million shs1.84 million shsCORTCorcept Therapeutics$22.80+2.7%$23.81$20.84▼$34.28$2.37B0.481.47 million shs795,534 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMTAimmune Therapeutics0.00%0.00%0.00%0.00%0.00%APHAAphria0.00%0.00%0.00%0.00%0.00%BKDBrookdale Senior Living+1.70%+5.29%+6.60%+20.86%+63.06%CORTCorcept Therapeutics-1.20%-1.99%-10.26%+2.54%-0.09%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAPHAAphriaN/AN/AN/AN/AN/AN/AN/AN/ABKDBrookdale Senior Living2.597 of 5 stars1.31.00.04.93.81.70.6CORTCorcept Therapeutics4.8188 of 5 stars3.51.00.04.53.03.33.1Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMTAimmune TherapeuticsN/AN/AN/AN/AAPHAAphriaN/AN/AN/AN/ABKDBrookdale Senior Living2.50Moderate Buy$7.507.76% UpsideCORTCorcept Therapeutics3.00Buy$39.3072.37% UpsideCurrent Analyst RatingsLatest BKD, PRY, APHA, CORT, and AIMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.004/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.002/16/2024CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $42.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMTAimmune TherapeuticsN/AN/AN/AN/A$1.66 per shareN/AAPHAAphria$405.96M12.00$0.09 per share166.43$4.80 per share3.20BKDBrookdale Senior Living$3.02B0.44$0.88 per share7.91$2.15 per share3.24CORTCorcept Therapeutics$482.38M4.92$0.97 per share23.47$4.92 per share4.63Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMTAimmune Therapeutics-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/AAPHAAphria-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/ABKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)CORTCorcept Therapeutics$106.14M$0.9524.0017.14N/A21.86%21.98%17.89%5/1/2024 (Confirmed)Latest BKD, PRY, APHA, CORT, and AIMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/ABKDBrookdale Senior Living-$0.17N/A+$0.17N/AN/AN/A 5/1/2024N/ACORTCorcept Therapeutics$0.18N/A-$0.18N/AN/AN/A 2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 million2/15/2024Q4 2023CORTCorcept Therapeutics$0.25$0.28+$0.03$0.28$129.27 million$135.41 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMTAimmune TherapeuticsN/AN/AN/AN/AN/AAPHAAphriaN/AN/AN/AN/AN/ABKDBrookdale Senior LivingN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMTAimmune Therapeutics0.737.537.40APHAAphria0.252.361.17BKDBrookdale Senior Living9.400.800.80CORTCorcept TherapeuticsN/A4.394.31OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMTAimmune Therapeutics74.47%APHAAphria10.30%BKDBrookdale Senior LivingN/ACORTCorcept Therapeutics93.61%Insider OwnershipCompanyInsider OwnershipAIMTAimmune Therapeutics13.75%APHAAphriaN/ABKDBrookdale Senior Living1.50%CORTCorcept Therapeutics19.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIMTAimmune Therapeutics22865.45 millionN/AOptionableAPHAAphria1,200316.80 millionN/AOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableCORTCorcept Therapeutics352104.08 million83.48 millionOptionableBKD, PRY, APHA, CORT, and AIMT HeadlinesSourceHeadlineLevi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlementaccesswire.com - April 25 at 12:30 PMCorcept Therapeutics (CORT) Scheduled to Post Earnings on Wednesdaymarketbeat.com - April 25 at 11:47 AMCorcept Therapeutics (NASDAQ:CORT) Raised to "Strong-Buy" at StockNews.comamericanbankingnews.com - April 25 at 2:20 AMCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.3%marketbeat.com - April 24 at 4:21 PMCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Callglobenewswire.com - April 24 at 4:05 PMCorcept Therapeutics gets grant for treating antipsychotic-induced weight gain with miricorilantpharmaceutical-technology.com - April 24 at 10:41 AMCorcept Therapeutics (NASDAQ:CORT) Receives Buy Rating from HC Wainwrightamericanbankingnews.com - April 24 at 4:42 AMPromising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s Relacorilantmarkets.businessinsider.com - April 23 at 7:28 PMCorcept Therapeutics (NASDAQ:CORT) Trading Up 7.5%marketbeat.com - April 23 at 3:43 PMCorcept Therapeutics (NASDAQ:CORT) Given Buy Rating at HC Wainwrightmarketbeat.com - April 23 at 1:49 PMCorcept (CORT) Posts Positive Data From Cushing's Syndrome Studyzacks.com - April 23 at 1:16 PMCorcept Therapeutics Target of Unusually Large Options Trading (NASDAQ:CORT)americanbankingnews.com - April 23 at 1:06 AMMid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quartermsn.com - April 22 at 3:34 PMCorcept falls after phase 3 results on Cushing's candidate doesn't include some datamsn.com - April 22 at 3:34 PMCorcept Therapeutics (NASDAQ:CORT) Sets New 52-Week Low at $20.84marketbeat.com - April 22 at 11:59 AMCorcept Therapeutics Sees Unusually Large Options Volume (NASDAQ:CORT)marketbeat.com - April 22 at 11:38 AMCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndromefinance.yahoo.com - April 22 at 10:33 AM45,200 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Louisiana State Employees Retirement Systemmarketbeat.com - April 21 at 5:08 AMCerity Partners LLC Has $2.41 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)marketbeat.com - April 19 at 5:13 AMQ3 2025 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Researchamericanbankingnews.com - April 19 at 3:02 AMLevi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlementaccesswire.com - April 18 at 12:15 PMZacks Research Weighs in on Corcept Therapeutics Incorporated's Q3 2025 Earnings (NASDAQ:CORT)marketbeat.com - April 18 at 6:31 AMCorcept Therapeutics (NASDAQ:CORT) Downgraded to "Buy" at StockNews.comamericanbankingnews.com - April 18 at 6:30 AMCorcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Up 5.5% in Marchamericanbankingnews.com - April 18 at 5:54 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s Portfolio3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesAll Headlines Company DescriptionsAimmune TherapeuticsNASDAQ:AIMTAimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.AphriaNASDAQ:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Brookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.Corcept TherapeuticsNASDAQ:CORTCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.